Table.

Characteristics of Patients With AE, by Age Group

Variable	Age Group
	0–17 Years (n = 751 655)*	18–74 Years (n = 809 293)*	75–99 Years (n = 175 909)*	Total (n = 640 572)*
Mean prevalence ofactive AE during a given year, %	12.3	5.1	8.7	6.9
Sensitivity analysis 1: Active disease defined only by prescriptions	8.8	3.8	7.9	5.2
Sensitivity analysis 2: Excluding persons with any record of potentially overlapping diagnoses	11.3	3.8	7.1	5.7
Median prescriptions during a given year (IQR), n
AnyAE-related therapy†	6(3–14)	5 (2–12)	7 (3–14)	6 (2–13)
Topical steroids or calcineurin inhibitors	2 (1–4)	2(1–5)	2(1–6)	2(1–5)
Patients with AE with ≥1 AE-related systemic treatment code during a given year, %	0.1	1.7	1.5	1.1
Patients with comorbid atopic disease during the study, %
≥1 diagnosis code for asthma	9.8	14.2	5.3	13.4
≥1 diagnosis code for allergies/rhinitis	13.8	25.1	7.8	21.7

AE = atopic eczema; IQR = interquartile range.

^*Numbers indicate the mean denominator for annual prevalence estimates across the age group.

^†lncludes topical skin preparations, topical steroids, topical calcineurin inhibitors, topical anti-infective treatments, and AE-related systemic treatments (including methotrexate, azathioprine, mycophenolate, cyclosporine, biologic agents, or phototherapy).